Doctors continue to prescribe anticholinergic medications to older patients without consistently informing them of the potential increased risk of dementia associated with these drugs, according to recent analyses of prescribing patterns and academic studies.
Anticholinergics, which block the neurotransmitter acetylcholine responsible for communication between brain and muscle cells, are commonly used in older adults to manage bladder problems, Parkinson’s disease, depression, and certain psychiatric conditions. More than four million people over the age of 65 currently take at least one anticholinergic drug, and many are prescribed multiple anticholinergics simultaneously, a practice that heightens the risk of adverse effects.
Research including a large 2023 study led by the University of Nottingham found that use of bladder-specific anticholinergics such as oxybutynin was associated with an 18% increased likelihood of developing dementia compared to those who did not take these drugs. The study analyzed health records of nearly one million individuals aged 55 and older over a period of up to 13 years, with an average dementia diagnosis age of 82. In contrast, the bladder medication mirabegron, which lacks anticholinergic properties, was not linked to a significant increase in dementia risk.
Despite these findings, regulatory bodies such as the Medicines and Healthcare Products Regulatory Agency (MHRA) have concluded that current evidence is insufficient to definitively establish causation between anticholinergic use and dementia, noting the challenges inherent in conducting large-scale experimental studies on this population. Consequently, warnings about dementia risk are often absent from patient information leaflets, although common side effects like falls, dry mouth, and blurred vision are typically mentioned.
Medical experts emphasize the need for greater caution and transparency. Geriatrician Lucy Pollock highlighted the absence of routine prescription audits or alert systems within prescribing software to flag anticholinergic use, which contributes to a broader issue of polypharmacy. Polypharmacy, defined as taking five or more medications concurrently, is prevalent among older adults in England, with almost eight million people over 50 on multiple prescriptions. This complexity increases the risk of drug interactions and hospital admissions.
Clinical guidelines from the National Institute for Health and Care Excellence (NICE) recommend minimizing anticholinergic burden, especially in frail older patients. However, professional bodies such as the Royal College of Surgeons of Edinburgh and the British Geriatrics Society have voiced concerns about ongoing widespread use of these medications without adequate consideration of safer alternatives. NHS data reveals that prescriptions for anticholinergic drugs more than doubled from 2.6 million in 2005 to 6.2 million last year.
NHS officials stress that anticholinergic drugs should be prescribed in line with clinical guidelines and only after thorough discussion of risks and benefits with patients or carers. The health service has undertaken extensive medication reviews, including 3.6 million last year focused on people living with frailty, to reduce unnecessary prescriptions. The MHRA advises that patients continue to take their medications as prescribed and consult healthcare professionals with any concerns.
As research continues, experts urge more proactive measures to inform patients of potential risks and consider alternative treatments to reduce anticholinergic exposure in older adults.